Special Issue

Recent Advances in Antivirals for Emerging Viruses (3rd Edition)

Message from the Guest Editor

The emergence of COVID-19 is a reminder that new transmissible viruses may have global social, health, and economic impacts. Recently developed biological tools (including rapid and efficient cloning and sequencing) have advanced scientific efforts to identify the viral enzymes of important novel and re-emerging human viruses (e.g., Dengue, West Nile, Zika, Chikungunya, influenza, and now coronaviruses). At the same time, drug discovery has expanded exponentially, resulting in vast libraries of compounds that can be employed to screen direct antiviral activity. This Special Issue will highlight recent advances in antiviral drug developments, and address the following domains:

- directly acting antivirals;
- modifiers of immune activation;
- inhibitors of specific cell activation pathways.

Guest Editor

Dr. James J. Kohler
Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA

Deadline for manuscript submissions

closed (31 May 2025)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/180390

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI